Seres Therapeutics
MCRB
79 hedge funds and large institutions have $344M invested in Seres Therapeutics in 2017 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 28 increasing their positions, 25 reducing their positions, and 11 closing their positions.
283% more call options, than puts
Call options by funds: $1.14M | Put options by funds: $298K
12% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 25
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1.5% less ownership
Funds ownership: 77.08% → 75.58% (-1.5%)
11% less funds holding
Funds holding: 89 → 79 (-10)
18% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 11
47% less capital inflows, than outflows
Capital inflows: $6.81M | Capital outflows: $12.7M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ARK Investment Management
St. Petersburg,
Florida
|
+$1.4M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.05M |
| 3 |
Spark Investment Management
New York
|
+$552K |
| 4 |
JP Morgan Chase
New York
|
+$516K |
| 5 |
D.E. Shaw & Co
New York
|
+$405K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$3.2M |
| 2 |
CQS Cayman
Camana Bay, Grand Cayman,
Cayman Islands
|
-$1.6M |
| 3 |
Portolan Capital Management
Boston,
Massachusetts
|
-$1.1M |
| 4 |
AG
Artal Group
Luxembourg
|
-$1.01M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$967K |
MCRB Hedge Fund Activity: Q1 2017 in Review
79 of the 4,036 institutional investors tracked by Wall St. Rank reported a position in Seres Therapeutics (MCRB) for Q1 2017, worth a combined $344M — up 12% from $308M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of MCRB and 9 opened new positions — a net loss of 2 holders — while 25 trimmed existing stakes and 28 added.
The largest buyer was ARK Investment Management, adding an estimated $1.4M. The largest seller was Federated Hermes, cutting an estimated $3.2M.
- 79 institutional investors held Seres Therapeutics (MCRB) as of Q1 2017, down from 89 in Q4 2016.
- Funds reported $344M of Seres Therapeutics stock for Q1 2017, up 12% quarter-over-quarter.
- 9 funds opened new Seres Therapeutics positions in Q1 2017 and 11 closed out, a net change of -2 holders.
- The largest Seres Therapeutics buyer in Q1 2017 was ARK Investment Management, an estimated $1.4M added.
- The largest Seres Therapeutics seller in Q1 2017 was Federated Hermes, an estimated $3.2M sold.
Based on aggregated 13F filings for Q1 2017.